别名 RANK配体、CD254、ODF + [13] |
简介 Cytokine that binds to TNFRSF11B/OPG and to TNFRSF11A/RANK. Osteoclast differentiation and activation factor. Augments the ability of dendritic cells to stimulate naive T-cell proliferation. May be an important regulator of interactions between T-cells and dendritic cells and may play a role in the regulation of the T-cell-dependent immune response. May also play an important role in enhanced bone-resorption in humoral hypercalcemia of malignancy (PubMed:22664871). Induces osteoclastogenesis by activating multiple signaling pathways in osteoclast precursor cells, chief among which is induction of long lasting oscillations in the intracellular concentration of Ca (2+) resulting in the activation of NFATC1, which translocates to the nucleus and induces osteoclast-specific gene transcription to allow differentiation of osteoclasts. During osteoclast differentiation, in a TMEM64 and ATP2A2-dependent manner induces activation of CREB1 and mitochondrial ROS generation necessary for proper osteoclast generation (By similarity). |
靶点 |
作用机制 RANKL抑制剂 |
在研机构 |
非在研适应症- |
最高研发阶段批准上市 |
首次获批国家/地区 美国 |
首次获批日期2024-03-05 |
靶点 |
作用机制 RANKL抑制剂 |
在研机构 |
原研机构 |
最高研发阶段批准上市 |
首次获批国家/地区 中国 |
首次获批日期2023-09-05 |
开始日期2024-07-31 |
申办/合作机构 |
开始日期2024-05-01 |
申办/合作机构 Xentria Inc初创企业 |
开始日期2024-04-09 |
申办/合作机构- |